Expression of EGFR and Molecules Downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) Pathways in Invasive Lung Adenocarcinomas Resected at a Single Institution
Table 2
Expression of EGFR, p-ERK1/2, p-STAT3, ERCC1, and Akt by immunohistochemistry, and clinicopathological characteristics in 96 patients with lung adenocarcinoma.
Group
EGFR mean score
value
pERK1/2 positivity (%)
value
p-STAT3 positivity (%)
value
p-Akt positivity (%)
value
ERCC1 positivity (%)
value
Sex
Male
122.4
0.19
7 (7.61)
0.5
14 (15.3)
0.2
4 (4.3)
0.4
18 (20.4)
0.6
Female
91.0
7 (7.61)
15 (16.4)
8 (8.6)
21 (23.8)
Age
Below 60 years
82.2
0.14
3 (3.2)
0.17
8 (8.7)
0.2
5 (5.3)
0.8
12 (13.6)
0.17
Above 60 years
177.8
11 (11.9)
21 (23)
7 (7.5)
27 (30.6)
Size/stage
T1
70.0
0.01
8 (8.7)
0.22
11 (12)
0.7
6 (6.4)
0.5
18 (20.4)
0.4
Greater than T1
129.1
6 (6.5)
18 (19.7)
6 (6.4)
21 (23.8)
Vascular invasion
Yes
80.1
0.01
2 (2.2)
0.05
11 (12.3)
0.9
2 (2.2)
0.05
12 (13.9)
0.2
No
141.7
12 (13.3)
18 (20.2)
11 (12)
26 (30.2)
Pleural invasion
Yes
90.4
0.07
2 (2.2)
0.3
8 (8.9)
0.5
1 (1.1)
0.1
10 (11.6)
0.7
No
142.1
13 (13.9)
21 (23.6)
11 (12)
28 (32.5)
High grade histology
Yes
155.5
<0.01
3 (3.2)
0.5
9 (9.8)
0.6
5 (5.3)
0.3
13 (14.7)
0.5
No*
84.4
11 (11.9)
20 (21.9)
7 (7.5)
26 (29.5)
Predominantly solid or acinar cribriform tumors (high grade) versus other subtypes.
